Biogen's Tau-Targeting Drug Shows Mixed Results in Alzheimer's Trial
Event summary
- Biogen presented phase 2 CELIA study results for diranersen (BIIB080) at AAIC on July 14, 2026.
- Study failed primary endpoint but showed strong biomarker effects and clinical signals at lower doses.
- Higher doses reduced tau more effectively, while the lowest dose showed the strongest clinical benefit.
- ADDF highlights discordance between biomarker and clinical findings as key question for future trials.
The big picture
Biogen's mixed results for diranersen highlight both the promise and complexity of targeting tau in Alzheimer's treatment. While anti-amyloid therapies exist, the field is increasingly focused on combination approaches that address multiple disease pathologies. The ADDF emphasizes the need to tackle tau as part of a broader precision medicine strategy, with 75% of current clinical trials exploring pathways beyond amyloid.
What we're watching
- Dosing Optimization
- How Biogen will reconcile the discordance between biomarker and clinical effects in designing phase 3 trials.
- Tau-Targeting Momentum
- Whether these results will accelerate investment in tau-targeting therapies as part of combination treatments for Alzheimer's.
- Pipeline Diversification
- The pace at which the Alzheimer's therapeutic pipeline expands beyond amyloid and tau to include other pathways like inflammation and metabolic dysfunction.